Price T Rowe Associates Inc. MD Reduces Stock Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS)

Price T Rowe Associates Inc. MD lowered its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 39.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 909,707 shares of the company's stock after selling 604,798 shares during the quarter. Price T Rowe Associates Inc. MD owned approximately 2.25% of Keros Therapeutics worth $14,402,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also modified their holdings of the company. AlphaQuest LLC boosted its holdings in shares of Keros Therapeutics by 469.0% in the fourth quarter. AlphaQuest LLC now owns 3,596 shares of the company's stock valued at $57,000 after acquiring an additional 2,964 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in Keros Therapeutics during the 4th quarter worth $90,000. Exchange Traded Concepts LLC purchased a new position in Keros Therapeutics during the 4th quarter worth $99,000. CANADA LIFE ASSURANCE Co grew its position in Keros Therapeutics by 207.8% during the 4th quarter. CANADA LIFE ASSURANCE Co now owns 7,371 shares of the company's stock worth $116,000 after purchasing an additional 4,976 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its stake in Keros Therapeutics by 19.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,589 shares of the company's stock valued at $136,000 after purchasing an additional 1,372 shares during the period. Hedge funds and other institutional investors own 71.56% of the company's stock.

Keros Therapeutics Stock Up 0.5 %

Shares of KROS opened at $14.65 on Friday. The company has a market capitalization of $594.95 million, a PE ratio of -2.81 and a beta of 1.39. Keros Therapeutics, Inc. has a 52-week low of $9.12 and a 52-week high of $72.37. The company has a 50-day simple moving average of $11.92 and a 200-day simple moving average of $26.32.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.36) by $0.22. The company had revenue of $3.04 million during the quarter, compared to the consensus estimate of $37.32 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. On average, research analysts anticipate that Keros Therapeutics, Inc. will post -4.74 EPS for the current year.

Insiders Place Their Bets

In other Keros Therapeutics news, major shareholder Adar1 Capital Management, Llc bought 934,258 shares of the business's stock in a transaction on Wednesday, April 9th. The stock was bought at an average price of $10.13 per share, for a total transaction of $9,464,033.54. Following the completion of the transaction, the insider now owns 4,392,737 shares in the company, valued at approximately $44,498,425.81. The trade was a 27.01 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 22.90% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on KROS shares. Cantor Fitzgerald lowered Keros Therapeutics from an "overweight" rating to a "neutral" rating in a report on Tuesday, January 21st. Scotiabank lowered their target price on Keros Therapeutics from $44.00 to $41.00 and set a "sector outperform" rating on the stock in a research note on Thursday, January 16th. Piper Sandler cut their price target on Keros Therapeutics from $40.00 to $15.00 and set an "overweight" rating for the company in a research note on Friday, January 17th. HC Wainwright reiterated a "buy" rating and issued a $40.00 price objective on shares of Keros Therapeutics in a research report on Tuesday, April 1st. Finally, Wedbush restated a "neutral" rating and set a $15.00 price objective on shares of Keros Therapeutics in a research report on Tuesday, April 1st. Six research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $40.33.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.

Want to see what other hedge funds are holding KROS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.